Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Huobahuagen Tablets plus tacrolimus for intermediate- and high-risk primary membranous nephropathy
ChiCTR2200056304Phase 4Recruiting
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Dec 2021
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of tacrolimus and colquhounia root tablet in idiopathic membranous glomerulonephritis (IMG) (2 arms), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoint: Complete remission and partial remission at 6 months. Started Dec 2021; status: recruiting.
02
Drugs
tacrolimuscolquhounia root tablet
03
Conditions
idiopathic membranous glomerulonephritis (IMG)
Beyond the preview
Go deeper on ChiCTR2200056304.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200056304.